Abstract
Cutaneous melanoma is the most deadly cutaneous neoplasm. In order to guide treatment decisions and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and 2016. Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations.
Highlights
The incidence of cutaneous melanoma is the highest in Europe and still rising
Grades of recommendations: A Directly based on Level I evidence B Directly based on Level II evidence or extrapolated recommendations from Level I evidence C Directly based on Level III evidence or extrapolated recommendations from Level I or II evidence D Directly based on Level IV evidence or extrapolated recommendations from Level I, II, or III evidence The purpose of these updated guidelines is to ensure the adequate management and treatment of melanoma patients in Switzerland
Patients with low-risk melanoma still tend to be over-treated, whereas the therapy and follow-up procedures for patients with high-risk or metastasising melanoma are sometimes inadequate, especially if the patients are managed outside centres of excellence
Summary
Cutaneous melanoma is the most deadly cutaneous neoplasm. In order to guide treatment decisions and followup of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and 2016. Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
